Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655085 | 1.00 | THRB (0.58) | THRBATML3MBTL1GAAHSD11B1 | |
| SCHEMBL8367374 | 0.90 | THRB (0.66) | THRBATML3MBTL1GAACHRM1 | |
| SCHEMBL4716522 | 0.86 | LMNA (0.49) | THRBATML3MBTL1GAAHSD11B1 | |
| SCHEMBL9774606 | 0.85 | THRB (0.59) | THRBATML3MBTL1GAAHSD11B1 | |
| SCHEMBL14450373 | 0.84 | THRB (0.52) | THRBATML3MBTL1GAAHSD11B1 | |
| SCHEMBL3255861 | 0.83 | EPHX1 (0.54) | L3MBTL1HSD11B1MEN1KMT2AALDH1A1 | |
| SCHEMBL2498330 | 0.83 | EPHX1 (0.54) | L3MBTL1HSD11B1MEN1KMT2AALDH1A1 | |
| SCHEMBL652761 | 0.83 | EPHX1 (0.54) | L3MBTL1HSD11B1MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2498984 | 0.81 | EPHX1 (0.52) | L3MBTL1HSD11B1MEN1KMT2AALDH1A1 | |
| SCHEMBL29267116 | 0.81 | SMN1; SMN2 (0.59) | HSD11B1CHRM2CHRM5KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-1688418-B1 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARM INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2286811-A1 | Chemokine receptor antagonists and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1688418-A2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | THRB 1822/4885ATM 4722/4885L3MBTL1 3786/4885 |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | THRB 1385/4885ATM 4394/4885L3MBTL1 4007/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | THRB 1385/4885ATM 4394/4885L3MBTL1 4007/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | THRB 1391/4885ATM 4415/4885L3MBTL1 4150/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | THRB 1385/4885ATM 4394/4885L3MBTL1 4007/4885 |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | THPO, NFATC1, HPGDS | THRB 2387/4885ATM 3965/4885L3MBTL1 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.